Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease
Open Access
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Neurobiology of Disease
- Vol. 121, 214-229
Abstract
No abstract availableKeywords
Funding Information
- NIH/NINDS (P51OD011092)
This publication has 87 references indexed in Scilit:
- Tissue-Specific Actions of Glucocorticoids on Apoptosis: A Double-Edged SwordCells, 2013
- Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's diseaseTranslational Psychiatry, 2012
- A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's diseaseJournal of Neurophysiology, 2012
- Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington diseaseJournal of Clinical Investigation, 2011
- Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's diseaseAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Hypothalamic mechanisms in cachexiaPhysiology & Behavior, 2010
- Neuroendocrine Disturbances in Huntington's DiseasePLOS ONE, 2009
- Brain‐derived neurotrophic factor over‐expression in the forebrain ameliorates Huntington’s disease phenotypes in miceJournal of Neurochemistry, 2007
- The corticoid environment: a determining factor for neural progenitors' survival in the adult hippocampusEuropean Journal of Neuroscience, 2004
- Adult neurogenesis is regulated by adrenal steroids in the dentate gyrusNeuroscience, 1994